S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

MESO Mesoblast Limited

16.00

0.46 (2.96%)

Pre Market

Last Updated: 05:21:51

Delayed by 15 minutes

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Article too big to display. Click here to view on the SEC website

Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Mesoblast Charts.

Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Mesoblast Charts.

Mesoblast Limited News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 27 February 2025 (13 hours ago) • Edgar (US Regulatory)

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
Wednesday 26 February 2025 (2 days ago) • GlobeNewswire Inc.

Mesoblast Financial Results and Corporate Update Webcast
Tuesday 25 February 2025 (3 days ago) • GlobeNewswire Inc.

Dr. Gregory George MD PhD Joins Mesoblast Board
Sunday 23 February 2025 (5 days ago) • GlobeNewswire Inc.

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
Thursday 13 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Wednesday 12 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Wednesday 12 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form F-3/A - Registration statement by foreign private issuers: [Amend]
Thursday 6 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Form F-3 - Registration statement by foreign private issuers
Wednesday 5 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Ryoncil® Commercial Launch Update and Product Pipeline
Thursday 30 January 2025 (4 weeks ago) • GlobeNewswire Inc.

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
Thursday 30 January 2025 (4 weeks ago) • GlobeNewswire Inc.

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
Wednesday 18 December 2024 (2 months ago) • GlobeNewswire Inc.

More Mesoblast Limited News Articles

Good Vibrations Shoes (PK)

ElectroMedical Technolog... (PK)

TPT Global Tech (PK)

Lightwave Logic

TransCode Therapeutics

Global Developments (PK)

Digital Brand Media and ... (PK)

Seven Arts Entertainment (PK)

Voip Pal Com (QB)

MineralRite (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions